Galectin Therapeutics
GALT
GALT
52 hedge funds and large institutions have $9.77M invested in Galectin Therapeutics in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
16% more funds holding
Funds holding: 45 → 52 (+7)
0.83% more ownership
Funds ownership: 10.65% → 11.48% (+0.83%)
Holders
52
Holding in Top 10
–
Calls
$866K
Puts
$672K
Top Buyers
| 1 | +$330K | |
| 2 | +$212K | |
| 3 | +$210K | |
| 4 |
BlackRock
New York
|
+$181K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
+$112K |
Top Sellers
| 1 | -$324K | |
| 2 | -$153K | |
| 3 | -$53.1K | |
| 4 |
TSS
Two Sigma Securities
New York
|
-$35K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$15K |